Sources

11 Total Sources

Eli Lilly Backs Foundayo Launch After $98 Million Debut as UAE Sales Signal Ex-US Strength

Left80%

Center20%

BioSpace16d ago

Eli Lilly Confident in Foundayo Launch Amid Strong Ex-US Sales

Bloomberg16d ago

Eli Lilly Boosts 2026 Sales Guidance to $87 Billion on Strong Drug Demand

Eli Lilly Tops Q2 Estimates, Raises Outlook on Zepbound, Mounjaro Sales Surge

International Business Times17d ago

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb | IBTimes

Here's How Much Traders See Eli Lilly Stock Moving After Earnings - AOL

finance.biggo.com16d ago

Novo Nordisk Q2 Operating Profit Beats Estimates Yet Plunges Over 6%; Investors Shrug Off Upgraded Full-Year Outlook — BigGo Finance

Investors | Eli Lilly and Company16d ago

Eli Lilly Reports 48% Revenue Growth in Q2 2026, Raises Full-Year Guidance on Mounjaro, Zepbound

LLY | 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 𝐐𝟐 𝟐𝟎𝟐𝟔 𝐄𝐚𝐫𝐧𝐢𝐧𝐠𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: Revenue: $22.97B (↑48% YoY) | GAAP EPS: $7.94 | Adjusted EPS: $8.38 👉 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ➤ 𝐔.𝐒. 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 increased 33% driven mainly by Zepbound

24/7 Wall St.16d ago

Eli Lilly Price Prediction: This Is Where The Stock Will End This Year - 24/7 Wall St.

Facebook16d ago

BREAKING: Novo Nordisk, maker of Ozempic and Wegovy, raised its full-year forecast after strong second-quarter profit driven by sales of a new Wegovy tablet, which launched in the US in January and

Stocktwits16d ago

PSKY Beats Q2 Estimates, Raises 2026 Outlook As CEO Stands Firm On $110B WBD Deal — But Stock Slips After-Hours